# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) ("Turning Point") today announced th...
Turning Point Therapeutics (NASDAQ: TPTX) has received positive feedback from the U.S. Food and Drug Administration (FDA) at a ...
Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targ...
Bristol Myers Squibb (NYSE:BMY) today has announced that Rhumba Merger Sub Inc. ("Offeror"), a wholly owned subsidiary ...
Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targ...
Upgrades
SVB Leerink analyst Andrew Berens downgrades Turning Point (NASDAQ:TPTX) from Outperform to Market Perform and lowers the pr...
Upgrades